Benzinga | Dec 20, 2021 08:04AM EST

Galecto Says Has Enrolled 10 Of Anticipated 16 Patients In Phase 2a MYLOX-1 Trial; Reiterates Expected Timing Of Multiple Data Readouts In 2022

Company has enrolled 10 of the targeted 16 patients in the trial



Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022

BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a publicly listed company focused on the development of novel treatments for fibrosis and cancer, today announced it has enrolled 10 of the anticipated 16 patients in its Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.

The open label MYLOX-1 trial (NCT04679870) is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GB2064 in 16 patients over 9 months. The trial will also assess the impact on fibrosis and quantification of the tissue targeting of GB2064, as well as other aspects of clinical response in myelofibrosis.

"We are very pleased to have enrolled over half of the targeted 16 patients in our MYLOX-1 trial. We are proud that the Galecto team continues to drive our clinical trials forward despite the challenging recruiting environment during the ongoing COVID-19 pandemic. We remain on track to report interim data in mid-2022 and topline data from the full trial in the second half of 2022," said Dr. Hans Schambye, CEO of Galecto. "We expect a data rich year in 2022 as we also anticipate reporting topline data from Part 2 of our liver cirrhosis GULLIVER-2 trial next year."

Myelofibrosis is a type of bone marrow cancer that causes scarring in the bone marrow and disrupts the body's normal production of blood cells, which can lead to multiple negative impacts and a significantly reduced quality of life and mortality.

LOXL2 is an enzyme that plays a key role in myelofibrosis and contributes to the fibrotic progression in this disease. Galecto's LOXL2 inhibitor, GB2064, has demonstrated potent inhibition of LOXL2 activity in cell-based assays and preclinical models and has successfully completed Phase 1 studies in healthy volunteers.